AEON · AEON Biopharma, Inc.
$0.24
+0.01 (+3.71%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, management has concluded that substantial doubt about our ability to continue as a going concern exists as conditions and events, considered in the aggregate, indicate that it is probable that we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this Report are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$11.98M
Shares
49.88M
Volume · Oct 21
105.96K
Avg daily vol (3M)
7.53M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.23
Open$0.24
Day$0.22–0.24
52W close$0.19–1.36
Avg vol 30d13.1M
Short int2.2M · 4.4% float · 1.0d
Short vol37%
DataJan 2023–Oct 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$54.62M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$3.43M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+355.6%
Year over year · more shares
Price change (1Y)
-80.0%
Trailing year
Short interest
4.4%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−67%
below
Price vs 50-day avg
−11%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
3%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−76%
trailing
YTD return
−79%
this year
Relative strength
−84%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
3 of 22 funds reported for Sep 30 · net +12.9K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.35% of float · ▼ -26.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
22 holders — mid 3-yr range
Squeeze score
46
elevated · 0–100
Fundamentals
EPS growth
−105%
Y/Y
Free cash flow
$-17.3M
Quant / Vol
risk profile
Volatility
105%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
14.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−67%
Bearish
Price vs 50-day avg
−11%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
3 of 22 funds reported for Sep 30 · net +12.9K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.35% of float · ▼ -26.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
22 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 3%
Range high $1
vs 200-day avg -67%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AEON
this stock
AEON Biopharma, Inc.
|
$11.98M | -79.0% | — | — | 4.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +13.5% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.6% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
PRE 14A
- Filed
- Oct 13, 2026
- This year
- 23
AEON Biopharma, Inc. will ask stockholders on December 15, 2026 to authorize one reverse stock split from 1-for-2 through 1-for-100 within 12 months, and add pre-funded warrant shares to evergreen calculations for its incentive plan and employee stock purchase plan.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AEON | +0.8% | -11.6% | -75.8% | -22.8% | -79.0% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +1.9% | -11.1% | -83.8% | -23.7% | -91.7% |